A multinational group known as GRAPPA has compiled a new set of treatment recommendations for psoriasis and psoriatic arthritis.
A multinational group has compiled a new set of treatment recommendations for psoriasis and psoriatic arthritis. Reporting at the American College of Rheumatology Annual Meeting in San Francisco, CA, Laura Coates of the University of Rochester, Rochester, NY, and colleagues there and at other institutions drafted the new treatment guidelines through consensus.
The group, known as GRAPPA, voted on six overarching principles developed through multiple iterations with significant agreement among both health care professions and research partners.
They did six separate literature reviews looking at best practices in treating arthritis, spondylitis, enthesitis, dactylitis, skin, and nail disease.
They also looked at comorbidities related to psoriatic arthritis.
Their work is organized by the type of psoriatic arthritis and drug recommendations are categorized as strong and weak. There are two conditions where drugs not recommended.
In axial psoriatic arthritis, biologic naive patients should not get disease-modifying antirheumatic drugs (DMARDs), IL61, or CD20i, the group decided. Patients with peripheral arthritis, those who are DMARD naive should not get IL12/23I, or IL17I, based on "lack of evidence" of effectiveness, GRAPPA wrote. In other cases, they made recommendations based on abstract data.
The new guidelines will be presented at the meeting in an abstract Nov. 10.